Patents Examined by Jeffrey Stucker
  • Patent number: 12215169
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: February 4, 2025
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 12202895
    Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 21, 2025
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, IMMUNE-ONC THERAPEUTICS, INC.
    Inventors: Zhiqiang An, Chengcheng Zhang, Ningyan Zhang, Xun Gui, Mi Deng, Tao Huang, Qiang Liu, X. Charlene Liao
  • Patent number: 12202840
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: January 21, 2025
    Assignee: AC Immune SA
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette, Heiko Kroth, Cedric Boudou
  • Patent number: 12195554
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of polysialic acid. The antibodies of the present technology are useful in methods for detecting and treating a polysialic acid-associated cancer in a subject in need thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 14, 2025
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Linlin Wang, Zhihao Wu, Mahiuddin Ahmed, Sarah M. Taldone, Steven M. Larson, Nai-Kong V. Cheung
  • Patent number: 12194000
    Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: January 14, 2025
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventor: David Weiner
  • Patent number: 12187763
    Abstract: An affinity chromatography resin comprising an anti-tissue factor antibody or antigen-binding fragment thereof attached to a base resin, and methods of using the same.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: January 7, 2025
    Assignee: ImmunityBio, Inc.
    Inventors: Hing C. Wong, Jin-an Jiao, Caitlin Prendes
  • Patent number: 12187807
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: August 18, 2023
    Date of Patent: January 7, 2025
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Patent number: 12180284
    Abstract: The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: December 31, 2024
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Hilario Ramos, Jensing Liu, Roger Waltzman
  • Patent number: 12173030
    Abstract: The invention provides compositions and methods for suppressing autoimmune components of neurodegenerative diseases and thereby providing therapeutic effects to patients suffering from such diseases. Compositions and methods include immunosuppressive moieties such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or protein that specifically binds one or more glial cell markers. Therapeutically effective doses of said compounds for treating neurodegenerative diseases including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases are disclosed.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 24, 2024
    Assignee: AZTherapies, Inc.
    Inventor: Philip G. Ashton-Rickardt
  • Patent number: 12173070
    Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: December 24, 2024
    Assignee: ABL BIO INC.
    Inventors: Eunyoung Park, Yangsoon Lee, Uijung Jung, YoungKwang Kim, Yeun Ju Kim, Youngdon Pak, Sang Hoon Lee, Weon-Kyoo You, Jaeho Jung, Lei Fang, Wenqing Jiang
  • Patent number: 12168681
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: December 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Patent number: 12161669
    Abstract: The current disclosure provides polypeptide constructs and cells comprising CDR3 regions of ?9. ?2 or both, that selectively bind a J-configuration of CD277 on a target cell. The disclosure also provides pharmaceutical compositions with the disclosed polypeptides or cells and methods of using these compositions in the treatment of cancer.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 10, 2024
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventors: Jürgen Herbert Ernst Kuball, Zsolt Sebestyen, Dennis Beringer, Anna Vyborova
  • Patent number: 12153056
    Abstract: Among the various aspects of the present disclosure is the provision of compositions for and methods of diagnosing, prognosing, and treating diabetes.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: November 26, 2024
    Assignee: Washington University
    Inventors: Emil R. Unanue, Xiaoxiao Wan, Cheryl Lichti
  • Patent number: 12145988
    Abstract: The present disclosure encompasses anti-TREM-2 antibodies that promote TREM-2 activation and methods of using the anti-TREM-2 agonist antibodies therapeutically.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: November 19, 2024
    Assignee: Washington University
    Inventors: David Holtzman, Jason Ulrich, Hong Jiang
  • Patent number: 12134771
    Abstract: A fusion protein which may comprise a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment for cytosine deamination at the target site. The fusion protein may comprise a first nCas9 fragment, a chimeric insertion fragment and a second nCas9 fragment from N-terminus to C-terminus, wherein the chimeric insertion fragment is TadA-TadA* for cytosine deamination at the target site. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Grant
    Filed: January 5, 2023
    Date of Patent: November 5, 2024
    Assignee: ShanghaiTech University
    Inventors: Yajing Liu, Shisheng Huang, Xingxu Huang
  • Patent number: 12123006
    Abstract: The present disclosure relates to the field of biotechnology, in particular to a base editing tool and use thereof. The present disclosure provides a fusion protein comprising a first nCas9 fragment, a chimeric insertion fragment, a second nCas9 fragment and two UGI fragments from N-terminus to C-terminus, wherein the chimeric insertion fragment is selected from APOBEC1 fragment or APOBEC3A fragment. The present disclosure provides a novel base editing tool that is compatible with insertion of various deaminases on the chimeric sites of nCas9. Compared with nCas9 terminal fusion base editor, the base editing tool of the present invention significantly reduce of off-targeting on both DNA and RNA, while maintaining specific targeted base editing efficiency, with higher specificity and favorable industrialization prospects.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: October 22, 2024
    Assignee: SHANGHAITECH UNIVERSITY
    Inventors: Yajing Liu, Shisheng Huang, Xingxu Huang
  • Patent number: 12122827
    Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: October 22, 2024
    Assignee: ASHER BIOTHERAPEUTICS, INC.
    Inventors: Yik Andy Yeung, Renee L. Greer, Henry C. Nguyen, David Liu, Byong Kang, Ivana Djuretic
  • Patent number: 12116423
    Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: October 15, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Meredith Hay, John Konhilas, Robin L. Polt, Evan Jones, Lajos Szabo
  • Patent number: 12098209
    Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 24, 2024
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Ki Joon Cho, Mijung Lee, Eun Jung Song, Ki Su Kim, Kwan Yub Kang, Eui Cheol Cho
  • Patent number: 12098177
    Abstract: Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-? secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-? secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: September 24, 2024
    Assignee: NantBio, Inc.
    Inventors: Kayvan Niazi, Clifford Anders Olson, Shiho Tanaka, Heather McFarlane